Zynerba Pharmaceuticals Inc (ZYNE)

NASDAQ
0.860
+0.010(+1.18%)
Pre Market
0.903
+0.043(+5.00%)
- Real-time Data
  • Volume:
    394,112
  • Day's Range:
    0.850 - 0.969
  • 52 wk Range:
    0.820 - 4.355
Unusual Pre-Market activity

Pre-market activity occurs before regular market hours and can be used to judge market strength and direction. Pre-market trading has some risk because of lower liquidity and more volatility than regular sessions.

ZYNE Overview

Prev. Close
0.85
Day's Range
0.85-0.969
Revenue
-
Open
0.86
52 wk Range
0.82-4.355
EPS
-0.931
Volume
394,112
Market Cap
37.38M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
432,814
P/E Ratio
-1.43
Beta
1.86
1-Year Change
-80.79%
Shares Outstanding
43,445,603
Next Earnings Date
Nov 14, 2022
What is your sentiment on Zynerba Pharma?
or
Market is currently closed. Voting is open during market hours.

Zynerba Pharmaceuticals Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Zynerba Pharmaceuticals Inc Analysis

Zynerba Pharmaceuticals Inc Company Profile

Zynerba Pharmaceuticals Inc Company Profile

Employees
28

Zynerba Pharmaceuticals, Inc. is primarily engaged in the pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, including Fragile X syndrome (FXS), autism spectrum disorder (ASD), and 22q11.2 deletion syndrome (22q). Cannabinoids are a class of compounds derived from Cannabis plants. Its two primary cannabinoids contained in cannabis are cannabidiol and tetrahydrocannabinol (THC). The Company is developing Zygel, the pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery and manufactured without the presence of THC. Zygel is being developed as a clear gel with once- or twice-daily dosing and is targeting the treatment of behavioral symptoms of FXS, ASD and 22q. It has evaluated Zygel targeting the reduction of seizures in patients with a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies (DEE).

Read More

Analyst Price Target

Average7.000 (+713.95% Upside)
High11
Low1
Price0.86
No. of Analysts5
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellSellStrong Sell
Technical IndicatorsSellStrong SellSellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell